{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-24-000062","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.991119+00:00","generated_at":"2026-06-02T07:10:20.643974+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xeris Biopharma Q1 total revenue $40.6M (+22% YoY); tightens FY 2024 guidance to $175M-$200M","bullets":["Net product revenue $40.3M (+24.8% YoY); Recorlev revenue $10.6M (+136.7%).","Net loss $19.0M ($0.14/share); cash $87.4M at March 31, 2024 (up from $72.5M).","Entered exclusive license with Amgen for XeriJect teprotumumab; up to $75M milestones plus royalties.","Entered collaboration with Beta Bionics for XeriSol glucagon in bi-hormonal pumps.","Tightened FY 2024 total revenue guidance to $175M-$200M; lowered Hayfin debt rate by 2.05%."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-24-000062","json":"https://secwatch.observer/filing/0001867096-24-000062.json","markdown":"https://secwatch.observer/filing/0001867096-24-000062.md","text":"https://secwatch.observer/filing/0001867096-24-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000062/0001867096-24-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000062/xers-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:10:20.643974+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0cefb01ebf5f45853bfd464e1bd27287d7d45b78","claim":"Xeris Biopharma Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $40,638, net income $19.0 million, or $0.14 per share. Guidance reaffirmed.","evidence_excerpt":"13,085 12,755 330 2.6 Recorlev 10,599 4,477 6,122 136.7 Product revenue, net 40,263 32,265 7,998 24.8 Royalty, contract and other revenue 375 931 (556) (59.7) Total revenue $ 40,638 $ 33,196 $ 7,442 22.4 Commercial Products • Gvoke® : First quarter net revenue was $16.6 million as compared to $15.0 million in the first quarter of 2023 – an increase of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000062/0001867096-24-000062-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$40,638"},{"label":"Net income","value":"$19.0 million, or $0.14 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}